Novo Nordisk’s Ryzodeg Does The Job With Fewer Injections


Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen for type 2 diabetes patients. 

Ryzodeg is a combination of two distinct insulin analogues , insulin degludec (Tresiba) and insulin aspart (Novolog) in the ratio of 70% and 30%, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.

The study was a 26-week randomised multinational phase 3b trial, where patients previously treated with basal insulin were randomised to a regimen of either twice daily Ryzodeg, or a basal-bolus regimen of once-daily insulin degludec plus two to four injections of insulin aspart. The study did not meet its primary endpoint of non-inferiority; however, the results showed that HbA1c was reduced for patients on either regimen, to 7.0% and 6.8% respectively, with no significant difference between the two regimens. Patients who received Ryzodeg experienced a numerically lower rate of overall and nocturnal confirmed hypoglycaemic episodes, 19% and 20% less, respectively. They also gained significantly less weight (p<0.05) over the course of the study and used a significantly lower daily insulin dose (12%; p<0.05) versus the basal-bolus regimen. 

Ryzodeg has been approved in Aruba, Brazil, Chile, Costa Rica, El Salvador, the EU, Hong Kong, Iceland, India, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland. 
Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x